Skip to main content

Peer Review reports

From: First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

Original Submission
18 Jan 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
31 Aug 2021 Reviewed Reviewer Report
6 Oct 2021 Author responded Author comments - Ava Hashempour
Resubmission - Version 4
6 Oct 2021 Submitted Manuscript version 4
10 Oct 2021 Author responded Author comments - Ava Hashempour
Resubmission - Version 5
10 Oct 2021 Submitted Manuscript version 5
15 Oct 2021 Reviewed Reviewer Report
20 Oct 2021 Author responded Author comments - Ava Hashempour
Resubmission - Version 6
20 Oct 2021 Submitted Manuscript version 6
21 Oct 2021 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
22 Oct 2021 Editorially accepted
24 Nov 2021 Article published 10.1186/s12876-021-01988-y

You can find further information about peer review here.

Back to article page